Gyre Therapeutics, Inc.
GYRENASDAQ
Healthcare
Biotechnology
$7.17
-0.06(-0.8%)
52W $6.65 – $11.50
Gyre Therapeutics, Inc.
Revenue breakdown: Product (95%), Contiva (2.5%), Etorel (2.1%).
$655MMkt Cap
$116MRev TTM
$5MNI TTM
127.7xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 12, 2026Gyre Therapeutics, Inc. (GYRE) reported strong revenue growth of 10.2% to $116.6 million for FY 2025 ended December 31, 2025, driven by $106.1 million from flagship ETUARY® (pirfenidone) for IPF, plus initial contributions from new launches Etorel® ($4.6 million) and Contiva® ($5.5 million), offsetting a decline in generic sales. Despite revenue expansion, net income fell 44.8% to $9.9 million and...
What Changed Recently
Fundamentals
How The Business Makes Money
Revenue by Segment
Product95%
Contiva2.5%
Etorel2.1%
Other Product0.5%
Company Profile
CIK0001124105
ISINUS4037831033
CUSIP403783103
Phone619 949 3681
Address12770 High Bluff Drive, San Diego, CA, 92130, US
SEC EDGAR